Tocilizumab therapy for persistent high-grade fever in systemic lupus erythematosus: two cases and a literature review

Chaoyi, Ma; Shrestha, Bikash; Li, Hui; Qiujin, Ding; Fu, Ping

doi:10.1177/03000605221088558

Cited by 9 publications

(3 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has also been used in an adolescent patient with SLE and a pleural effusion [173]. It was also used successfully in SLE patients with persistent high grade fever and who were resistant to treatment with antibiotics and corticosteroids [174]. Tocilizumab administration has been shown to have beneficial effects in lupus patients with arthritis [175].…”

Section: Interleukin Inhibitors 431 Tocilizumabmentioning

confidence: 99%

Current Treatment Approach, Emerging Therapies and New Horizons in Systemic Lupus Erythematosus

Athanassiou

2023

Life

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE), the prototype of systemic autoimmune diseases is characterized by extreme heterogeneity with a variable clinical course. Renal involvement may be observed and affects the outcome. Hydroxychloroquine should be administered to every lupus patient irrespective of organ involvement. Conventional immunosuppressive therapy includes corticosteroids, methotrexate, cyclophosphamide, mycophenolate mofetil, azathioprine, cyclosporine and tacrolimus. However, despite conventional immunosuppressive treatment, flares occur and broad immunosuppression is accompanied by multiple side effects. Flare occurrence, target organ involvement, side effects of broad immunosuppression and increased knowledge of the pathogenetic mechanisms involved in SLE pathogenesis as well as the availability of biologic agents has led to the application of biologic agents in SLE management. Biologic agents targeting various pathogenetic paths have been applied. B cell targeting agents have been used successfully. Belimumab, a B cell targeting agent, has been approved for the treatment of SLE. Rituximab, an anti-CD20 targeting agent is also used in SLE. Anifrolumab, an interferon I receptor-targeting agent has beneficial effects on SLE. In conclusion, biologic treatment is applied in SLE and should be further evaluated with the aim of a good treatment response and a significant improvement in quality of life.

show abstract

Section: Interleukin Inhibitors 431 Tocilizumabmentioning

confidence: 99%

Current Treatment Approach, Emerging Therapies and New Horizons in Systemic Lupus Erythematosus

Athanassiou

2023

Life

View full text Add to dashboard Cite

show abstract

“…Tocilizumab is currently in Phase I clinical trials for SLE (Table S3). Preliminary data have shown that tocilizumab may be a good alternative treatment for patients with SLE who do not respond to high-dose glucocorticoids, but further studies are needed [131,132].…”

Section: Common Therapeutics For Sle Ssc and Ramentioning

confidence: 99%

Immunotherapy Strategy for Systemic Autoimmune Diseases: Betting on CAR-T Cells and Antibodies

Chasov,

Zmievskaya,

Ganeeva

et al. 2024

Antibodies

View full text Add to dashboard Cite

Systemic autoimmune diseases (SAIDs), such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc) and rheumatoid arthritis (RA), are fully related to the unregulated innate and adaptive immune systems involved in their pathogenesis. They have similar pathogenic characteristics, including the interferon signature, loss of tolerance to self-nuclear antigens, and enhanced tissue damage like necrosis and fibrosis. Glucocorticoids and immunosuppressants, which have limited specificity and are prone to tolerance, are used as the first-line therapy. A plethora of novel immunotherapies have been developed, including monoclonal and bispecific antibodies, and other biological agents to target cellular and soluble factors involved in disease pathogenesis, such as B cells, co-stimulatory molecules, cytokines or their receptors, and signaling molecules. Many of these have shown encouraging results in clinical trials. CAR-T cell therapy is considered the most promising technique for curing autoimmune diseases, with recent successes in the treatment of SLE and SSc. Here, we overview novel therapeutic approaches based on CAR-T cells and antibodies for targeting systemic autoimmune diseases.

show abstract

“…It has also been used in an adolescent patient with SLE and a pleural effusion [172]. It has also been used successfully in SLE patients with persistent high grade fever, resistant to treatment with antibiotics and corticosteroids [173]. Tocilizumab administration has been shown to have beneficial effects in lupus patients with arthritis [174].…”

Section: Tocilizumabmentioning

confidence: 99%

Current Treatment Approach, Emerging Therapies and New Horizons in Systemic Lupus Erythematosus

Athanassiou¹,

Athanassiou²

2023

Preprint

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE), the prototype of systemic autoimmune diseases is characterized by extreme heterogeneity with a variable clinical course. Renal involvement may be observed and affects the outcome. Hydroxychloroquine is the cornerstone of lupus treatment. Conventional immunosuppressive therapy includes corticosteroids, methotrexate, azathioprine, cyclosporine and tacrolimus. Cyclophosphamide and mycophenolate mofetil may also be used. However, despite conventional immunosuppressive treatment flares occur and broad immunosuppression is accompanied by multiple side effects. Flare occurrence, target organ involvement, side effects of broad immunosuppression, increased knowledge of the pathogenetic mechanisms involved in SLE pathogenesis as well as the availability of biologic agents has led to the application of biologic agents in SLE management. Biologic agents targeting various pathogenetic paths have been applied. B cell targeting agents have been used successfully. Belimumab, a B cell targeting agent has been approved for the treatment of SLE. Rituximab, an anti-CD20 targeting agent is also used in SLE. Anifrolumab, an interferon I receptor targeting agent has beneficial effects on SLE. In conclusion, biologic treatment is applied in SLE and should be further evaluated with the aim of a good treatment response and a significant improvement in quality of life.

show abstract

Tocilizumab therapy for persistent high-grade fever in systemic lupus erythematosus: two cases and a literature review

Cited by 9 publications

References 35 publications

Current Treatment Approach, Emerging Therapies and New Horizons in Systemic Lupus Erythematosus

Current Treatment Approach, Emerging Therapies and New Horizons in Systemic Lupus Erythematosus

Immunotherapy Strategy for Systemic Autoimmune Diseases: Betting on CAR-T Cells and Antibodies

Current Treatment Approach, Emerging Therapies and New Horizons in Systemic Lupus Erythematosus

Contact Info

Product

Resources

About